Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 5/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961367 | 0.87 | AKR1B1 (0.36) | AKR1B1SRD5A1PTGDR2PLA2G7 | |
| SCHEMBL2961364 | 0.87 | AKR1B1 (0.36) | AKR1B1SRD5A1PTGDR2PLA2G7 | |
| SCHEMBL7573966 | 0.86 | AKR1B1 (0.36) | AKR1B1SRD5A1PTGDR2PLA2G7CYP19A1 | |
| SCHEMBL7542265 | 0.85 | AKR1B1 (0.35) | AKR1B1SRD5A1PTGDR2PLA2G7CYP19A1 | |
| SCHEMBL7554328 | 0.85 | AKR1B1 (0.39) | AKR1B1SRD5A1PTGDR2PLA2G7CYP19A1 | |
| SCHEMBL7568343 | 0.76 | AKR1B1 (0.34) | AKR1B1CYP19A1 | |
| SCHEMBL7543411 | 0.76 | CYP19A1 (0.34) | CYP19A1 | |
| SCHEMBL7552682 | 0.74 | AKR1B1 (0.35) | AKR1B1CYP19A1 | |
| SCHEMBL7536095 | 0.74 | BACE1 (0.42) | — | |
| SCHEMBL8186472 | 0.73 | PGR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | AKR1B1 1760/4885SRD5A1 644/4885PTGDR2 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.